trending Market Intelligence /marketintelligence/en/news-insights/trending/gvkf3ojarmsjopda66qx-a2 content esgSubNav
In This List

Lawsuit against Intercept Pharmaceutical directors dismissed by US court

Blog

Funding Social and Affordable Housing: A Credit Perspective

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals


Lawsuit against Intercept Pharmaceutical directors dismissed by US court

Intercept Pharmaceuticals Inc. said a U.S. court granted a motion to dismiss a shareholder lawsuit which alleged that company directors breached their fiduciary duty.

The Supreme Court of the State of New York, County of New York dismissed the suit, Solak v. Fundaro, et al., which was filed August 2017, purportedly on behalf of the company.

The suit alleged that company directors violated the company's nonexecutive director compensation practices.

The New York-based biopharmaceutical company said the ruling is subject to appeal.